Regeneron Pharmaceuticals' Enterprise Value rose 451.93% to -$8.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$8.6 billion, marking a year-over-year increase of 451.93%. This contributed to the annual value of -$8.6 billion for FY2025, which is 451.93% up from last year.
As of Q4 2025, Regeneron Pharmaceuticals' Enterprise Value stood at -$8.6 billion, which was up 451.93% from -$8.4 billion recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Enterprise Value registered a high of -$3.5 billion during Q1 2021, and its lowest value of -$10.8 billion during Q4 2023.
For the 5-year period, Regeneron Pharmaceuticals' Enterprise Value averaged around -$7.9 billion, with its median value being -$8.4 billion (2025).
Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 10122.72% in 2022, then soared by 2384.95% in 2025.
Regeneron Pharmaceuticals' Enterprise Value (Quarter) stood at -$5.7 billion in 2021, then tumbled by 35.96% to -$7.7 billion in 2022, then crashed by 40.07% to -$10.8 billion in 2023, then rose by 16.9% to -$9.0 billion in 2024, then increased by 4.52% to -$8.6 billion in 2025.
Its Enterprise Value stands at -$8.6 billion for Q4 2025, versus -$8.4 billion for Q3 2025 and -$7.5 billion for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value